II
PTGX icon

Inspire Investing’s Protagonist Therapeutics PTGX Stock Holding History

Inspire Investing’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,938
Closed -$461K – 1159
2025
Q3 		$461K Sell
6,938
-346
-5% -$19.7K 0.04% 369
2025
Q2 		$403K Sell
7,284
-14,550
-67% -$698K 0.04% 326
2025
Q1 		$1.06M Buy
21,834
+11,279
+107% +$473K 0.13% 180
2024
Q4 		$407K Sell
10,555
-25,959
-71% -$1.13M 0.05% 365
2024
Q3 		$1.64M Buy
36,514
+26,280
+257% +$1.06M 0.17% 128
2024
Q2 		$355K Sell
10,234
-2,106
-17% -$61.7K 0.04% 419
2024
Q1 		$357K Sell
12,340
-4,442
-26% -$121K 0.04% 701
2023
Q4 		$385K Sell
16,782
-1,828
-10% -$32K 0.04% 488
2023
Q3 		$310K Buy
+18,610
New +$361K 0.04% 423

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Inspire Investing's PTGX Position: Q4 2025 in Review

Inspire Investing sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 6,938 shares — an estimated $461K sold.

Inspire Investing first reported a position in PTGX in Q3 2023 and held it in 9 quarters. The position peaked at $1.64M in Q3 2024. 316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Inspire Investing reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Inspire Investing sold 6,938 Protagonist Therapeutics shares in Q4 2025, an estimated $461K.
  • Inspire Investing first reported a position in Protagonist Therapeutics in Q3 2023 and held it in 9 quarters.
  • Inspire Investing's Protagonist Therapeutics position peaked at $1.64M in Q3 2024.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Inspire Investing's 13F filing for Q4 2025, filed 17 Feb 2026.